Physician profile
Peter B Toman
NPI 1245372010
$4,545.48
in general payments reported to CMS, 2019-2025
10 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $194 · 2021: $358 · 2022: $857 · 2023: $1,047 · 2024: $461 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380 · Consulting Fee: $390 · Entertainment: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.29 |
| Consulting Fee | $390.00 |
| Entertainment | $123.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,052.67 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,222.41 | 2019-2025 | Dailies, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $407.09 | 2022-2025 | Infuse, Biotrue One Day |
| Oyster Point Pharma, INC. | $269.77 | 2022-2024 | Tyrvaya |
| Optos, INC. | $213.64 | 2022-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.59 | 2019-2021 | |
| Visioneering Technologies, INC. | $93.99 | 2020-2024 | |
| Shire North American Group INC | $65.96 | 2019 | |
| Biotissue Holdings INC. | $30.36 | 2019-2021 | |
| Allergan, INC. | $25.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Toman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.